Startseite>>Signaling Pathways>> Cell Cycle/Checkpoint>> PLK>>Wortmannin

Wortmannin (Synonyms: KY 12420)

Katalog-Nr.GC12338

Wortmannin ist ein hochpotenter direkter Inhibitor der PI3-Kinase, ursprünglich aus Pilzen gewonnen.

Products are for research use only. Not for human use. We do not sell to patients.

Wortmannin Chemische Struktur

Cas No.: 19545-26-7

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
80,00 $
Auf Lager
5mg
61,00 $
Auf Lager
10mg
88,00 $
Auf Lager
20mg
142,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Product has been cited by 2 publications

Description Protocol Chemical Properties Product Documents Related Video Related Products

Wortmannin is a highly potent direct inhibitor of PI3-kinase specificity originally derived from fungi (1,2). This inhibition is irreversible and non-competitive with an IC50 of 3 nM[2][3]. Wortmannin does not inhibit PI4 kinase, protein kinase C, or protein tyrosine kinases[4].

In Jurkat cell, at the concentrations of wortmannin commonly used to inhibit PI 3-kinases, PLK1 is also significantly inhibited[5]. In Swiss 3T3 cells, Wortmannin is a selective and reversible phosphatidylinositol 3-kinase inhibitor with an IC50 value of 1.9 nM[4].PI3-kinase is involved in the signal transduction pathway responsible for histamine secretion following stimulation of Fc epsilon RI and that wortmannin blocks these responses through direct interaction with the catalytic subunit of this enzyme[1].

Wortmannin treatment significantly slower the growth rate of murine C3H mammary tumor and human MCF-7 breast cancer xenograft. A dose of 1 mg/kg Wortmannin for 7 days decrease the tumor burdens in mice with established murine C3H mammary tumors by 54% relative to controls. Human MCF-7 breast cancer xenograft burdens are decreased by 97% relative to controls after 14 days of 1 mg/kg Wortmannin beginning 1 day after tumor implantation[6]. Wortmannin inhibits myosin light chain phosphorylation and contraction in rat aorta. As an inhibitor of MLCK, wortmannin can be used as a vasodilator and anti-inflammatory agent[7].

References:
[1]: Yano H, Nakanishi S, et,al. Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells. J Biol Chem. 1993 Dec 5;268(34):25846-56. PMID: 7503989.
[2]: Moon EK, Kim SH, et,al. Autophagy inhibitors as a potential antiamoebic treatment for Acanthamoeba keratitis. Antimicrob Agents Chemother. 2015 Jul;59(7):4020-5. doi: 10.1128/AAC.05165-14. Epub 2015 Apr 20. PMID: 25896709; PMCID: PMC4468686.
[3]: Liu Y, Jiang N, et,al. Polo-like kinases inhibited by wortmannin. Labeling site and downstream effects. J Biol Chem. 2007 Jan 26;282(4):2505-11. doi: 10.1074/jbc.M609603200. Epub 2006 Nov 29. PMID: 17135248.
[4]: Powis G, Bonjouklian R, et,al. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Res. 1994 May 1;54(9):2419-23. PMID: 8162590.
[5]: Liu Y, Shreder KR, et,al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. Chem Biol. 2005 Jan;12(1):99-107. doi: 10.1016/j.chembiol.2004.11.009. PMID: 15664519.
[6]: Lemke LE, Paine-Murrieta GD, et,al. Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase. Cancer Chemother Pharmacol. 1999;44(6):491-7. doi: 10.1007/s002800051123. PMID: 10550570.
[7]: Nakanishi S, Kakita S, et,al.Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem. 1992 Feb 5;267(4):2157-63. PMID: 1733924.

Bewertungen

Review for Wortmannin

Average Rating: 5 ★★★★★ (Based on Reviews and 29 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Wortmannin

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.